"A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)"@en . "Ricobendazole"@en . . . . . . . . . . . "Albenza"@en . . . . . "Albendazole is rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine. Urinary excretion of albendazole sulfoxide is a minor elimination pathway with less than 1% of the dose recovered in the urine. Biliary elimination presumably accounts for a portion of the elimination as evidenced by biliary concentrations of albendazole sulfoxide similar to those achieved in plasma."@en . . "Zentel"@en . . . . . "# Molina AJ, Merino G, Prieto JG, Real R, Mendoza G, Alvarez AI: Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. Eur J Pharm Sci. 2007 May;31(1):16-24. Epub 2007 Feb 6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17350811 # Oxberry ME, Reynoldson JA, Thompson RC: The binding and distribution of albendazole and its principal metabolites in Giardia duodenalis. J Vet Pharmacol Ther. 2000 Jun;23(3):113-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11110097 # Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11343808 # Haque A, Hollister WS, Willcox A, Canning EU: The antimicrosporidial activity of albendazole. J Invertebr Pathol. 1993 Sep;62(2):171-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/8228321"@en . . . . . . . "Gyurik, R.J. and Theodorides, VJ.; US. Patent 3,915,986; October 28,1975; assigned to Smith Kline Corp."@en . . . "Albendazole"@en . . "(5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester"@en . "Symptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching."@en . . "Rycobendazole"@en . . . "Albendazole"@en . . . . . . . . . "Albendazol"@en . . . . . . "Helminthic Microorganisms"@en . . . . "70% bound to plasma protein"@en . . . . . . "Poorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Oral bioavailability appears to be enhanced when coadministered with a fatty meal (estimated fat content 40 g)"@en . "Terminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg)."@en . "O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate"@en . . . "For the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus."@en . "Albendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies."@en . "Eskazole"@en . . "approved"@en . . . "Proftril"@en . "54965-21-8"@en . "Valbazen"@en . "Albendazolum"@en . "5-(Propylthio)-2-carbomethoxyaminobenzimidazole"@en .